1-3 of 3
Carol Wong
Close
Sort by
Journal Articles

Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, Armin Ghobadi, Krish Patel, Jae H Park, Ian W. Flinn, Prutha Shah, Carol Wong, Cara Bickers, Peter Szabo, Lilly Wong, Bahram Valamehr, Siminder Atwal, Yu-Waye Chu, Rebecca Elstrom, Paolo Strati
Journal: Blood
Blood (2021) 138 (Supplement 1): 823.
https://doi.org/10.1182/blood-2021-151185
Published: 2021
Journal Articles

Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, MD PhD, Zuzan Cayci, MD, Dixie Lewis, RN,BA, Joseph E. Maakaron, MD, Murali Janakiram, MD, Andersen Bartz, Steven Payne, BS, Carol Wong, MPH, Sarah Cooley, MD, Bahram Valamehr, PhD, Yu-Waye Chu, MD, Jeffrey S. Miller, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8.
https://doi.org/10.1182/blood-2020-141606
Published: 2020
Journal Articles

HIF–prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques

Matthew M. Hsieh, N. Seth Linde, Aisha Wynter, Mark Metzger, Carol Wong, Ingrid Langsetmo, Al Lin, Reginald Smith, Griffin P. Rodgers, Robert E. Donahue, Stephen J. Klaus, John F. Tisdale
Journal: Blood
Blood (2007) 110 (6): 2140–2147.
https://doi.org/10.1182/blood-2007-02-073254
Published: 2007